Anita Wagner
Biographic Data
| ID | 5546976 |
|---|---|
| NAME | Anita Wagner |
| GIVEN NAMES | Anita |
| FAMILY NAME | Wagner |
| SIGNATURE | WAGNER A |
| AFFILIATIONS | Division of Health Policy and Insurance Research, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA |
| VERIFIED | No |
| TOTAL WORKS | 5 |
| TOTAL CITATIONS | 5 |
| AUTHOR COUNT | 5 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 1998 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 1 |
Preventive Drug Lists Reduce Income-Related Disparities in Medication Adherence Over 2 Years
BACKGROUND: Employers add Preventive Drug Lists (PDLs) to commercial insurance plans to reduce out-of-pocket payments for medicines that treat important chronic illnesses. OBJECTIVE: This study examined the impact of PDLs among patients with pre-existing diabetes. RESEARCH DESIGN: Interrupted time series design with difference-in-difference analysis. SUBJECTS: We identified 5575 patients aged 12-64 with diabetes whose employers adopted PDL covera…
The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China
INTRODUCTION: New targeted therapies have changed cancer treatment in the past decades. However, high prices of targeted anticancer medications have increased economic burden for both patients and health insurance systems. In July 2017, China implemented combined medication price negotiation and mandatory reimbursement policies for 15 targeted anticancer medications. This study assesses effects of the policy on hospital procurement prices, volume…
How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China
How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study Background Evidence is lacking about the impact of emerging government health insurance coverage inclusion on patient utilization and affordability of expensive anti-cancer medicines and insurance sustainability in China
Household Expenditures for Medicines and the Role of Free Medicines in the Brazilian Public Health System
Objectives. We sought to investigate, across different socioeconomic groups, the proportion of household medicine expenses that were paid by households and the proportion paid by the Brazilian national health system. Methods. We carried out a survey in Porto Alegre, Brazil, that included 2988 individuals of all ages. We defined 2 expenditure variables: “out-of-pocket medicines value” (the sum of retail prices of all medicines used by family membe…
Translating Health Status Questionnaires and Evaluating Their Quality
Household Expenditures for Medicines and the Role of Free Medicines in the Brazilian Public Health System
Objectives. We sought to investigate, across different socioeconomic groups, the proportion of household medicine expenses that were paid by households and the proportion paid by the Brazilian national health system. Methods. We carried out a survey in Porto Alegre, Brazil, that included 2988 individuals of all ages. We defined 2 expenditure variables: “out-of-pocket medicines value” (the sum of retail prices of all medicines used by family membe…
Translating Health Status Questionnaires and Evaluating Their Quality
Household Expenditures for Medicines and the Role of Free Medicines in the Brazilian Public Health System
Objectives. We sought to investigate, across different socioeconomic groups, the proportion of household medicine expenses that were paid by households and the proportion paid by the Brazilian national health system. Methods. We carried out a survey in Porto Alegre, Brazil, that included 2988 individuals of all ages. We defined 2 expenditure variables: “out-of-pocket medicines value” (the sum of retail prices of all medicines used by family membe…
How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China
How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study Background Evidence is lacking about the impact of emerging government health insurance coverage inclusion on patient utilization and affordability of expensive anti-cancer medicines and insurance sustainability in China
The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China
INTRODUCTION: New targeted therapies have changed cancer treatment in the past decades. However, high prices of targeted anticancer medications have increased economic burden for both patients and health insurance systems. In July 2017, China implemented combined medication price negotiation and mandatory reimbursement policies for 15 targeted anticancer medications. This study assesses effects of the policy on hospital procurement prices, volume…
Preventive Drug Lists Reduce Income-Related Disparities in Medication Adherence Over 2 Years
BACKGROUND: Employers add Preventive Drug Lists (PDLs) to commercial insurance plans to reduce out-of-pocket payments for medicines that treat important chronic illnesses. OBJECTIVE: This study examined the impact of PDLs among patients with pre-existing diabetes. RESEARCH DESIGN: Interrupted time series design with difference-in-difference analysis. SUBJECTS: We identified 5575 patients aged 12-64 with diabetes whose employers adopted PDL covera…
Business (4 works) · Medicine (4 works) · Economic and Financial Impacts of Cancer (3 works) · Environmental health (3 works) · Health care (3 works) · Health Systems, Economic Evaluations, Quality of Life (3 works) · Pharmaceutical Economics and Policy (3 works) · Actuarial science (2 works) · China (2 works) · Demography (2 works)